Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Recruiting · NCT04410796 · Registry updated 2026-09-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-09-11 | NCT04410796 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Guardant Health, Inc. | 14 |
| Memorial Sloan Kettering Cancer Center | 753 |
18 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.